Co-Authors
This is a "connection" page, showing publications co-authored by Carlo Salvarani and Pamela Mancuso.
Connection Strength
1.019
-
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia. Clin Exp Rheumatol. 2020 Nov-Dec; 38(6):1215-1222.
Score: 0.229
-
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. Arthritis Rheumatol. 2021 01; 73(1):48-52.
Score: 0.229
-
Response to: 'COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study' by Cuceoglu et al. Ann Rheum Dis. 2020 Jul 06.
Score: 0.223
-
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis. 2020 07; 79(7):986-988.
Score: 0.221
-
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. Rheumatology (Oxford). 2021 10 09; 60(SI):SI25-SI36.
Score: 0.061
-
Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020 09 29; 24(1):589.
Score: 0.057